A recent bioinformatics study combining proteomic and genomic approaches in AML, showed that there was no tumor specific cell surface antigen, and that complex combinatorial targeting strategies may be required for antibody-based T approaches to target AML (35). The gene discussed is CD53; the disease is neoplasm.